Michael A. Mussallem Sells 49,100 Shares of Edwards Lifesciences Corp (EW) Stock

Edwards Lifesciences Corp (NYSE:EW) CEO Michael A. Mussallem sold 49,100 shares of the company’s stock in a transaction dated Wednesday, May 3rd. The stock was sold at an average price of $109.71, for a total transaction of $5,386,761.00. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Michael A. Mussallem also recently made the following trade(s):

  • On Friday, April 28th, Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $109.78, for a total transaction of $5,390,198.00.
  • On Thursday, February 16th, Michael A. Mussallem sold 49,100 shares of Edwards Lifesciences Corp stock. The stock was sold at an average price of $89.63, for a total transaction of $4,400,833.00.

Edwards Lifesciences Corp (NYSE:EW) last announced its quarterly earnings results on Tuesday, April 25th. The medical research company reported $0.94 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $0.82 by $0.12. The company had revenue of $883.50 million during the quarter, compared to analyst estimates of $776.51 million. Edwards Lifesciences Corp had a return on equity of 25.00% and a net margin of 19.22%. The firm’s revenue was up 26.7% on a year-over-year basis. During the same period in the prior year, the firm posted $0.71 earnings per share.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corp (NYSE:EW)

ILLEGAL ACTIVITY WARNING: This news story was originally published by Markets Daily and is owned by of Markets Daily. If you are accessing this news story on another website, it was copied illegally and republished in violation of US and international copyright and trademark legislation. The correct version of this news story can be viewed at https://www.themarketsdaily.com/2017/05/20/edwards-lifesciences-corp-ew-ceo-sells-5386761-00-in-stock-updated.html.

Large investors have recently made changes to their positions in the company. BlackRock Inc. raised its stake in shares of Edwards Lifesciences Corp by 2,184.9% in the first quarter. BlackRock Inc. now owns 14,003,695 shares of the medical research company’s stock valued at $1,317,326,000 after buying an additional 13,390,818 shares in the last quarter. Norges Bank purchased a new stake in shares of Edwards Lifesciences Corp during the fourth quarter valued at approximately $217,484,000. Alliancebernstein L.P. raised its stake in shares of Edwards Lifesciences Corp by 29.8% in the first quarter. Alliancebernstein L.P. now owns 6,366,425 shares of the medical research company’s stock valued at $598,890,000 after buying an additional 1,459,921 shares in the last quarter. MARSHALL WACE ASIA Ltd purchased a new stake in shares of Edwards Lifesciences Corp during the first quarter valued at approximately $126,959,000. Finally, Marshall Wace North America L.P. purchased a new stake in shares of Edwards Lifesciences Corp during the first quarter valued at approximately $126,959,000. Institutional investors own 83.99% of the company’s stock.

A number of equities analysts have commented on EW shares. Cowen and Company reiterated an “outperform” rating and issued a $120.00 target price on shares of Edwards Lifesciences Corp in a report on Tuesday, March 28th. Zacks Investment Research upgraded shares of Edwards Lifesciences Corp from a “hold” rating to a “buy” rating and set a $127.00 target price for the company in a report on Tuesday. Northland Securities restated a “positive” rating and set a $105.00 price objective on shares of Edwards Lifesciences Corp in a report on Thursday, February 2nd. Leerink Swann downgraded shares of Edwards Lifesciences Corp from an “outperform” rating to a “market perform” rating in a report on Thursday, February 2nd. Finally, Credit Suisse Group AG set a $120.00 price objective on shares of Edwards Lifesciences Corp and gave the company a “buy” rating in a report on Wednesday, February 8th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company. Edwards Lifesciences Corp currently has a consensus rating of “Buy” and an average price target of $119.77.

About Edwards Lifesciences Corp

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

12 Month Chart for NYSE:EW

Receive News & Ratings for Edwards Lifesciences Corp Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corp and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply